XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

Stock Information for XOMA Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About XOMA Corporation

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO(TM) (clindamycin phosphate) Vaginal Gel 2%
Actym Therapeutics Appoints Thomas Smart as CEO
XOMA Corporation Announces Closing of Tender Offer
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE - AGTI), Landos Biopharma, Inc. (Nasdaq - LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq - KNTE)
XOMA Declares Quarterly Preferred Stock Dividends
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Whole Earth Brands, Inc. (Nasdaq - FREE), Kinnate Biopharma Inc. (Nasdaq - KNTE), Societal CDMO Check Corp. (Nasdaq - SCTL), California BanCorp (Nasdaq - CALB)
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.